CXCL9/10/11 can recruit immune cells, including CD8+ T cells, Th1 cells, and NK cells, to reach tumor sites, thereby inhibiting the progression of colorectal cancer through the binding of CXCR3 protein to immune cell surface sites [28]. This evidence concerns the gene CD8A and neoplasm.